Niagen Bioscience Inc. unveils investor presentation highlighting NAD+ market growth and product pipeline

Reuters11-05

<a href="https://laohu8.com/S/NAGE">Niagen Bioscience</a> Inc. unveils investor presentation highlighting NAD+ market growth and product pipeline

Niagen Bioscience Inc. released a corporate presentation highlighting its position as a leading authority on NAD+ with over 100 patents and a strong intellectual property portfolio. The company reported $124.7 million in revenue and $20.4 million in net income for the last twelve months ending in the third quarter of 2025. As of September 30, 2025, Niagen Bioscience reported $64.3 million in cash and no debt. The company's business is diversified across consumer health, IV and injectables, pharmaceuticals, and skincare, with significant revenue generated from its Tru Niagen® supplement. Niagen Bioscience collaborates with leading research institutions and has an active pipeline of clinical trials, particularly in areas such as Parkinson's disease and ataxia. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581762901?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581762901","market":"nz","top_or_hot":-1,"title":"Niagen Bioscience Inc. unveils investor presentation highlighting NAD+ market growth and product pipeline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> Inc. unveils investor presentation highlighting NAD+ market growth and product pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Niagen Bioscience Inc. released a corporate presentation highlighting its position as a leading authority on NAD+ with over 100 patents and a strong intellectual property portfolio. The company reported $124.7 million in revenue and $20.4 million in net income for the last twelve months ending in the third quarter of 2025. As of September 30, 2025, Niagen Bioscience reported $64.3 million in cash and no debt. The company's business is diversified across consumer health, IV and injectables, pharmaceuticals, and skincare, with significant revenue generated from its Tru Niagen® supplement. Niagen Bioscience collaborates with leading research institutions and has an active pipeline of clinical trials, particularly in areas such as Parkinson's disease and ataxia. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Niagen Bioscience Inc. unveils investor presentation highlighting NAD+ market growth and product pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNiagen Bioscience Inc. unveils investor presentation highlighting NAD+ market growth and product pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 05:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NAGE\">Niagen Bioscience</a> Inc. unveils investor presentation highlighting NAD+ market growth and product pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Niagen Bioscience Inc. released a corporate presentation highlighting its position as a leading authority on NAD+ with over 100 patents and a strong intellectual property portfolio. The company reported $124.7 million in revenue and $20.4 million in net income for the last twelve months ending in the third quarter of 2025. As of September 30, 2025, Niagen Bioscience reported $64.3 million in cash and no debt. The company's business is diversified across consumer health, IV and injectables, pharmaceuticals, and skincare, with significant revenue generated from its Tru Niagen® supplement. Niagen Bioscience collaborates with leading research institutions and has an active pipeline of clinical trials, particularly in areas such as Parkinson's disease and ataxia. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NAGE","symbol_name":"Niagen Bioscience","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL7sb60T:1","article_id":"2581762901","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581762901","pubTimestamp":1762291800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Niagen Bioscience Inc. released a corporate presentation highlighting its position as a leading authority on NAD+ with over 100 patents and a strong intellectual property portfolio. The company reported $124.7 million in revenue and $20.4 million in net income for the last twelve months ending in the third quarter of 2025. As of September 30, 2025, Niagen Bioscience reported $64.3 million in cash and no debt. The company's business is diversified across consumer health, IV and injectables, pharmaceuticals, and skincare, with significant revenue generated from its Tru Niagen supplement. Niagen Bioscience collaborates with leading research institutions and has an active pipeline of clinical trials, particularly in areas such as Parkinson's disease and ataxia. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, thi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NAGE":"Niagen Bioscience","BK4121":"生命科学工具和服务"},"translate_title":"Niagen Bioscience Inc.发布投资者演示文稿，重点介绍NAD+市场增长和产品线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NAGE":0.9},"content_text":"Niagen Bioscience Inc. unveils investor presentation highlighting NAD+ market growth and product pipeline\n    \n\n        Niagen Bioscience Inc. released a corporate presentation highlighting its position as a leading authority on NAD+ with over 100 patents and a strong intellectual property portfolio. The company reported $124.7 million in revenue and $20.4 million in net income for the last twelve months ending in the third quarter of 2025. As of September 30, 2025, Niagen Bioscience reported $64.3 million in cash and no debt. The company's business is diversified across consumer health, IV and injectables, pharmaceuticals, and skincare, with significant revenue generated from its Tru Niagen® supplement. Niagen Bioscience collaborates with leading research institutions and has an active pipeline of clinical trials, particularly in areas such as Parkinson's disease and ataxia. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581762901","isCrawlerRequest":true}